Sara Zareei joined the lab as a PhD Student in October 2026, funded by the EASTBIO doctoral training partnership. Sara will be working on RNA-binding protein mechanisms in fungi.

Sara joins with ten years of research experience in biochemistry, molecular modeling, and bioinformatics. She has published nearly twenty research papers, showcasing a strong track record of scholarly contributions to the field of biochemistry and bioinformatics. Sara’s research contributions include establishing a database of anti-cancer peptides, PeptiHub, featuring advanced searching capabilities and integrated machine learning algorithms, contributing significantly to cancer research and drug discovery efforts.

Sara has a BSc in Biology from the University of Zabol, and an MSc in Biochemistry from Kharazmi University, both in Iran. She has demonstrated expertise as a university lecturer for ten years, enhancing teaching and communication skills to engage biology and medical students in complex concepts effectively.

Selected Papers:

• “Systematic Investigation of Key Drivers of Lung Adenocarcinoma: A Focus on Genes, Pathways, and miRNAs. Cancer Investigation (2026): 1-14.”
  • “Computational disruption of paired helical filaments (PHFs) assembly using Milk Lactalbumin-derived peptides against Alzheimer’s disease. Journal of Functional Foods 130 (2025): 106853.”
  • “Assessment of dynamic removal mechanism of non-steroidal anti-inflammatory biomolecules in the aqueous environments by a novel covalent organic framework. Journal of Molecular Graphics and Modelling 137 (2025): 109006.”
  • “Targeting GSK-3β with Peptide Inhibitors: A Rational Computational Strategy for Alzheimer’s Disease Intervention. bioRxiv (2024): 2024-12.”
  • “In silico anti-alzheimer study of phytochemicals from Lamiaceae family through GSK3-β inhibition. Scientific Reports 14, no. 1 (2024): 834.”
  • “PeptiHub: a curated repository of precisely annotated cancer-related peptides with advanced utilities for peptide exploration and discovery. Database 2024 (2024): baae092.”
  • “Various concentrations of hesperetin induce different types of programmed cell death in human breast cancerous and normal cell lines in a ROS-dependent manner. Chemico-biological interactions 382 (2023): 110642.”
  • “Computational design of fusion proteins against ErbB2-amplified tumors inspired by ricin toxin. Frontiers in Molecular Biosciences 10 (2023): 1098365.”
  • “Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19. British Journal of Clinical Pharmacology 88, no. 10 (2022): 4403-4411.”
  • “Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region. Computers in biology and medicine 146 (2022): 105625.”
  • “Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence. Immunity, inflammation and disease 10, no. 6 (2022): e628.”
  • “Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches. Frontiers in pharmacology 13 (2022): 996005.”
  • “Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis. Immunity, inflammation and disease 9, no. 4 (2021): 1197-1208.”
  • “Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamic studies. Research in Pharmaceutical Sciences 15, no. 3 (2020): 226.”
  • “Inhibition of liver alanine aminotransferase and aspartate aminotransferase by hesperidin and its aglycone hesperetin: an in vitro and in silico study. Life sciences 178 (2017): 49-55.”